2024年ASCO肝细胞癌治疗进展  

Current progress and advances in hepatocellular carcinoma:highlights from 2024 ASCO annual meeting

作　　者：成远 朱小东 Cheng Yuan;Zhu Xiaodong(Cancer Center of PLA,Eastern Theater Command General Hospital,Nanjing 210002,China;Department of Liver Surgery and Transplantation,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]解放军东部战区总医院全军肿瘤中心,江苏南京210002 [2]复旦大学附属中山医院肝肿瘤外科,上海200032

出　　处：《实用肿瘤杂志》2024年第4期305-310,共6页Journal of Practical Oncology

摘　　要：2024年美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年会于2024年5月31日在美国芝加哥召开。今年大会的主题是“癌症治疗的艺术与科学:从关怀到治愈”。本次大会上报道了多项肝细胞癌(hepatocellular carcinoma,HCC)领域的重磅研究,涵盖晚期系统治疗、局部联合系统治疗和围手术期治疗等。部分研究结果将改变临床实践并推动肝癌领域的发展。本文重点介绍大会HCC相关研究结果,探讨HCC的治疗热点、问题和未来发展方向。The 2024 annual meeting of the American Society of Clinical Oncology(ASCO)was held on May 31st,2024,in Chicago,USA.The theme of this year's conference is"The Art and Science of Cancer Care:From Comfort to Cure".This conference reported many im-portant studies in the field of hepatocellular carcinoma(HCC),including advanced systemic therapy,locoregional therapy in combination with systemic therapy,perioperative therapy,etc.These results may change the clinical practice and promote the development of HCC.This article focuses on the research on HCC at the conference and discusses the hot spots,problems,and future directions.

关 键 词：肝细胞癌 美国临床肿瘤学会 治疗 

分 类 号：R735.7[医药卫生—肿瘤]